El-Galaly, Tarec Christoffer1; Hutchings, Martin9; Mylam, Karen Juul10; de Nully Brown, Peter10; Bukh, Anne11; Johnsen, Hans Erik12; Kamper, Peter13; Loft, Annika10; Iyer, Victor5; Gormsen, Lars Christian14; Nielsen, Anne Lerberg10; Bøgsted, Martin2; d'Amore, Francesco10
1 The Faculty of Medicine, Aalborg University, VBN2 Aalborg University Hospital, The Faculty of Medicine, Aalborg University, VBN3 Klinik Medicin, The Faculty of Medicine, Aalborg University, VBN4 Blodsygdomme (Hæmatologi), The Faculty of Medicine, Aalborg University, VBN5 Klinik Diagnostik, The Faculty of Medicine, Aalborg University, VBN6 Klinisk Fysiologi og Nuklearmedicin, The Faculty of Medicine, Aalborg University, VBN7 The Faculty of Engineering and Science, Aalborg University, VBN8 Department of Mathematical Sciences, The Faculty of Engineering and Science, Aalborg University, VBN9 Institut for Klinisk Medicin10 unknown11 Hæmatologisk Afdeling, Aalborg Sygehus12 Department of Clinical Medicine, The Faculty of Medicine, Aalborg University, VBN13 Hæmatologisk Afd. R, THG14 Institut for Klinisk Medicin - Klinisk fysiologi og nuclearmedicin, SKS
fewer cases with stage I disease and more with skeletal involvement
F-18-Fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is a highly accurate staging method in classical Hodgkin lymphoma (cHL). We retrospectively compared the staging results obtained in two large cohorts of patients with cHL diagnosed before (n = 324) and after (n = 406) the introduction of PET/CT staging in a retrospective study. In PET/CT staged patients, stage I disease was less frequent (16% vs. 27%, p <0.001) while stage IV disease was more frequent (17% vs. 10%, p = 0.02). Imaging-detected skeletal involvement was recognized more often in PET/CT staged patients (17% vs. 2%, p <0.001), and the presence of focal skeletal PET/CT lesions was associated with higher risk of progression (hazard ratio [HR] 1.96, 95% confidence interval [CI]: 1.14-3.36). The German Hodgkin Study Group (GHSG) risk classification (early, intermediate, advanced disease) predicted outcome in PET/CT staged patients. In conclusion, PET/CT led to higher disease stages, and the more frequently diagnosed skeletal lesions may be an adverse prognostic factor.
Leukemia and Lymphoma, 2014, Vol 55, Issue 10, p. 2349-2355